Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ODYY HUGE NEWS OUT!!!
Odyssey Group International to Acquire Concussion Drug Asset from Prevacus, Inc.
Press Release | 01/11/2021
All Stock Transaction
Phase 1 Clinical Trial Site, Protocol and CRO Established
IRVINE, CA / ACCESSWIRE / January 11, 2021 / Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to announce it has entered into a definitive agreement to acquire drug candidate PRV-002, a concussion drug therapeutic compound (mild traumatic brain injury (mTBI)), from Prevacus, Inc. (“Prevacus”) www.prevacus.com.
The definitive agreement has been signed and the transaction is expected to close by the end of February 2021, the transaction is conditional on Prevacus shareholder approval and other customary closing conditions.
There are more than 3 million sports and recreational concussions in the U.S. each year with an additional estimated 1.5 million that go unreported. These figures do not include a high number of concussions sustained in other high-risk incidents including motor vehicle accidents and elderly falls. Given the high incidence rate of concussion and its impact on patient care, the market for a treatment is estimated to be over $2 billion dollars annually.
Several notable professional athletes have endorsed Prevacus and its drug development effort, including Brett Favre, who has long been an investor in Prevacus and endorsed the science in hopes of bringing a therapeutic treatment for concussion to market. See the Prevacus website "news" section for other notable pro-athletes who have endorsed this effort; https://prevacus.com/news/.
Dr. Jake Vanlandingham, Prevacus Chief Executive Officer, will join Odyssey and continue to be instrumental in the development of PRV-002 focused on a treatment for concussion (mild traumatic brain injury (mTBI)). Dr. Vanlandingham, stated, "We are very excited to join forces with Odyssey in further development of the first drug to treat concussion. The Odyssey management group and funding mechanism will immediately allow us to continue the development of our unique nanoparticle drug in the nasal device by dramatically enhancing PRV-002 delivery to the brain," said Dr. Vanlandingham. "The concussion drug has been proven to be safe and effective in animal models and preparations are underway for a Phase 1 human clinical trial this year."
Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "We have been in a joint partnership with Prevacus for the past couple of years, and have been able to witness the early development and progress of PRV-002 and its potential for treatment of concussion. We are now thrilled to own the asset, have Dr. Vanlandingham join us in bringing it to a Phase 1 human clinical trial and have Odyssey shareholders directly benefit in the potential value created by PRV-002. We look forward to closing the all-stock acquisition by the end of February."
Concussion has become an epidemic in sports, military and elderly populations. The heterogenous nature of a traumatic brain injury requires a treatment that can work on many molecular fronts. PRV-002, through gene amplification has shown to reduce swelling, inflammation and oxidative stress simultaneously. Animal toxicology data shows a significant safety margin. Animal brain biodistribution studies show drug availability in less than 5-minutes.
About Prevacus, Inc.
Prevacus, Inc. is a biopharmaceutical company developing drug candidates with the potential to advance treatment in the fields of traumatic brain injury and other neurological disorders. The Company's first two development candidates (PRV-002 and PreVPro) represent breakthrough strategy for treating concussion working at the molecular level to simultaneously reduce inflammation, swelling, impaired cerebral blood flow and oxidative stress.
For more information visit: http://www.prevacus.com.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to close on the agreement in a timely manner, successfully complete a Phase 1 clinical trial, the economic slowdown affecting companies, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Media and Investors Contacts:
p619-832-2900
info@odysseygi.com
ClearThink
$ODYY Low float Something brewing...
$ODYY something brewing....
With more room to grow $GSFI
I would think that these leases that were signed are just the begining of many more to come. JMHO $GSFI
Sure does look that way. $GSFI!!
Something good!! Up 17% today $GSFI
It sure is. Like what they're doing!! $GSFI
I love the model of leasing up dead space to implement solar. Genius idea, especially when the foot print comes at a cheap price. $GSFI
An how would you know this "insider information" if true? Were you part of it? please enlighten us?
I like the moves $GSFI is making!!
$ODYY NEWS OUT!! Medical Co.
Odyssey Group International Advances Development of its Save A Life Choking Rescue Device
Press Release | 12/16/2020
Promising Test Results Leads to Design Improvements
IRVINE, CA / ACCESSWIRE / December 16, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to provide the following update on the development of its Save A Life choking rescue device. Product development and design partner Tanaka Kapec Design Group (TKDG) has continued to advance the product development with the ultimate goal of filing a submission to the FDA for the life-saving choking rescue device.
TKDG has identified, researched, designed and tested the suction interface tip that allows for effective removal of the lodged mass.. The improved design relates to the aperture diameter and aperture shape and has been optimized for the product. TKDG conducted testing with principal food items that are often a cause for choking. Additionally, testing focused on tips in conjunction with the pump and negative pressure with various food items. Such recommendations have led to to improved ergonomics, increased power with high efficiency and ease of use.
Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "We continue to advance the development of our Save A Life choking rescue device with our eyes on an FDA submission by the end of 2021, assuming we have access to the capital needed. The work by TKDG and its discovery was productive related to relationships between aperture size at tip, pressure and food size. Preliminary results are promising, and we look forward to continuing our work with TKDG."
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions.
Media and Investors Contacts:
p619-832-2900
info@odysseygi.com
$ODYY NEWS OUT. Medical Co.
Odyssey Group International Advances Development of its Save A Life Choking Rescue Device
Press Release | 12/16/2020
Promising Test Results Leads to Design Improvements
IRVINE, CA / ACCESSWIRE / December 16, 2020 / Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to provide the following update on the development of its Save A Life choking rescue device. Product development and design partner Tanaka Kapec Design Group (TKDG) has continued to advance the product development with the ultimate goal of filing a submission to the FDA for the life-saving choking rescue device.
TKDG has identified, researched, designed and tested the suction interface tip that allows for effective removal of the lodged mass.. The improved design relates to the aperture diameter and aperture shape and has been optimized for the product. TKDG conducted testing with principal food items that are often a cause for choking. Additionally, testing focused on tips in conjunction with the pump and negative pressure with various food items. Such recommendations have led to to improved ergonomics, increased power with high efficiency and ease of use.
Odyssey Chairman and Chief Executive Officer Michael Redmond, commented, "We continue to advance the development of our Save A Life choking rescue device with our eyes on an FDA submission by the end of 2021, assuming we have access to the capital needed. The work by TKDG and its discovery was productive related to relationships between aperture size at tip, pressure and food size. Preliminary results are promising, and we look forward to continuing our work with TKDG."
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTCQB:ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
For more information, visit: http://www.odysseygi.com
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including economic slowdown affecting companies, our ability to successfully develop products, rapid change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions.
Media and Investors Contacts:
p619-832-2900
info@odysseygi.com
Nice won't be long!! $DGDM
BB add ODYY to your watchlist, something brewing at the biotech company....
$DGDM NEWS OUT!!
DGDM Ramps Up Preparations for Launch of Its Proven Disruptive Pesticide Product Targeted to MJ Growers
Newsfile Corp.
Mon, November 30, 2020, 8:00 AM EST
Flower Mound, Texas--(Newsfile Corp. - November 30, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today updated progress ahead of the expected EPA approval of MiteXstream, its disruptive biopesticide targeted initially at cannabis growers.
Disruptive Advantage Nearing Approval. Fabian Deneault, President of DGDM and developer of MiteXstream, stated, "As we await the expected December 2020 EPA approval, our potential distribution partners are eager to show growers everywhere the amazing cost-benefit to be realized by using MiteXstream on their valuable crops throughout the entire grow cycle. Plant-based MiteXstream treats spider mites and other pests and outbreaks of mold and mildew through the day of harvest without state testing failures - that is our disruptive competitive advantage. In fact, we continue to believe that, due to MiteXstream's efficacy, our company will become a Major Cannabis Innovator in the minds of industry players."
Cannabis Production Growth: 2020- 2025. US recreational and medical cannabis industry sales are expected to be $19 billion for 2020, $24 billion for 2021 and, by 2025, with the four additions this month and expected newcomers, including New York, industry sales are expected to reach $45 billion (Source: Brightfield Group).
In-Field Private Party Testing. Over the past year, the Company has had private parties from California to the East Coast, including We'd, a Montana-licensed Medical Marijuana Dispensary, testing MiteXstream. In each case, MiteXstream proved effective in protecting cannabis plants from pests throughout the growth cycle, shortly after sprouting through the day of harvest.
MiteXstream's efficacy can be seen in this short video:
$DGDM NEWS OUT!!!
DGDM Ramps Up Preparations for Launch of Its Proven Disruptive Pesticide Product Targeted to MJ Growers
Newsfile Corp.
Mon, November 30, 2020, 8:00 AM EST
Flower Mound, Texas--(Newsfile Corp. - November 30, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today updated progress ahead of the expected EPA approval of MiteXstream, its disruptive biopesticide targeted initially at cannabis growers.
Disruptive Advantage Nearing Approval. Fabian Deneault, President of DGDM and developer of MiteXstream, stated, "As we await the expected December 2020 EPA approval, our potential distribution partners are eager to show growers everywhere the amazing cost-benefit to be realized by using MiteXstream on their valuable crops throughout the entire grow cycle. Plant-based MiteXstream treats spider mites and other pests and outbreaks of mold and mildew through the day of harvest without state testing failures - that is our disruptive competitive advantage. In fact, we continue to believe that, due to MiteXstream's efficacy, our company will become a Major Cannabis Innovator in the minds of industry players."
Cannabis Production Growth: 2020- 2025. US recreational and medical cannabis industry sales are expected to be $19 billion for 2020, $24 billion for 2021 and, by 2025, with the four additions this month and expected newcomers, including New York, industry sales are expected to reach $45 billion (Source: Brightfield Group).
In-Field Private Party Testing. Over the past year, the Company has had private parties from California to the East Coast, including We'd, a Montana-licensed Medical Marijuana Dispensary, testing MiteXstream. In each case, MiteXstream proved effective in protecting cannabis plants from pests throughout the growth cycle, shortly after sprouting through the day of harvest.
MiteXstream's efficacy can be seen in this short video:
$DGDM NEWS OUT!!!!
DGDM Ramps Up Preparations for Launch of Its Proven Disruptive Pesticide Product Targeted to MJ Growers
Newsfile Corp.
Mon, November 30, 2020, 8:00 AM EST
Flower Mound, Texas--(Newsfile Corp. - November 30, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today updated progress ahead of the expected EPA approval of MiteXstream, its disruptive biopesticide targeted initially at cannabis growers.
Disruptive Advantage Nearing Approval. Fabian Deneault, President of DGDM and developer of MiteXstream, stated, "As we await the expected December 2020 EPA approval, our potential distribution partners are eager to show growers everywhere the amazing cost-benefit to be realized by using MiteXstream on their valuable crops throughout the entire grow cycle. Plant-based MiteXstream treats spider mites and other pests and outbreaks of mold and mildew through the day of harvest without state testing failures - that is our disruptive competitive advantage. In fact, we continue to believe that, due to MiteXstream's efficacy, our company will become a Major Cannabis Innovator in the minds of industry players."
Cannabis Production Growth: 2020- 2025. US recreational and medical cannabis industry sales are expected to be $19 billion for 2020, $24 billion for 2021 and, by 2025, with the four additions this month and expected newcomers, including New York, industry sales are expected to reach $45 billion (Source: Brightfield Group).
In-Field Private Party Testing. Over the past year, the Company has had private parties from California to the East Coast, including We'd, a Montana-licensed Medical Marijuana Dispensary, testing MiteXstream. In each case, MiteXstream proved effective in protecting cannabis plants from pests throughout the growth cycle, shortly after sprouting through the day of harvest.
MiteXstream's efficacy can be seen in this short video:
$DGDM NEWS OUT!!!!
DGDM Ramps Up Preparations for Launch of Its Proven Disruptive Pesticide Product Targeted to MJ Growers
Newsfile Corp.
Mon, November 30, 2020, 8:00 AM EST
Flower Mound, Texas--(Newsfile Corp. - November 30, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today updated progress ahead of the expected EPA approval of MiteXstream, its disruptive biopesticide targeted initially at cannabis growers.
Disruptive Advantage Nearing Approval. Fabian Deneault, President of DGDM and developer of MiteXstream, stated, "As we await the expected December 2020 EPA approval, our potential distribution partners are eager to show growers everywhere the amazing cost-benefit to be realized by using MiteXstream on their valuable crops throughout the entire grow cycle. Plant-based MiteXstream treats spider mites and other pests and outbreaks of mold and mildew through the day of harvest without state testing failures - that is our disruptive competitive advantage. In fact, we continue to believe that, due to MiteXstream's efficacy, our company will become a Major Cannabis Innovator in the minds of industry players."
Cannabis Production Growth: 2020- 2025. US recreational and medical cannabis industry sales are expected to be $19 billion for 2020, $24 billion for 2021 and, by 2025, with the four additions this month and expected newcomers, including New York, industry sales are expected to reach $45 billion (Source: Brightfield Group).
In-Field Private Party Testing. Over the past year, the Company has had private parties from California to the East Coast, including We'd, a Montana-licensed Medical Marijuana Dispensary, testing MiteXstream. In each case, MiteXstream proved effective in protecting cannabis plants from pests throughout the growth cycle, shortly after sprouting through the day of harvest.
MiteXstream's efficacy can be seen in this short video:
Awesome start $SSET. Let's see where we are at noon!! GLTY
$SSET only 16 million float. Should be gone soon. JMHO
$SSET HUGE NEWS!! Adding today!!!
I'll be adding some $SSET. Great NEWS!!!
GM BB what's cooking for today?
Pretty good day today. Mostle green. $DGDM!!!
$DGDM NEWS OUT
Election Results Expand the Legal Cannabis Footprint by Four States, Boosting Prospective Sales for DGDM's Proven Disruptive Pesticide Product Targeted to MJ Growers
Newsfile Corp.
Newsfile Corp
Flower Mound, Texas--(Newsfile Corp. - November 12, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today addressed the expanding prospects, post-election, for its disruptive pesticide product, MiteXstream, following favorable legal cannabis votes in Arizona, New Jersey, Montana and South Dakota.
2020-2025 Growth. US recreational and medical cannabis industry sales are expected to be $19 billion for 2020, $24 billion for 2021 and, by 2025, with the four additions this month and expected newcomers, including New York, sales are industry sales are expected to reach $45 billion (Source: Brightfield Group).
Big Indoor Grows Need Protection. "Indoor grows are quite susceptible to troublesome infestations of spider mites and other pests and outbreaks of mold and mildew - the pests can kill the plants, while mold and mildew can spoil the harvest. Plant-based MiteXstream treats these problems the grow through the day of harvest without state testing failures - that is our disruptive competitive advantage," said Fabian Deneault, President of DGDM. "We continue to anticipate a December 2020 EPA approval of MiteXstream."
East Coast Density. "As legal cannabis continues to penetrate the densely populated Northeast Corridor - D.C. to Boston - the demand on grows to produce cannabis products will require efficient production techniques, and we believe MiteXstream will be a significant player in that effort," Mr. Deneault added.
DGDM: Doing Good, Doing More. DGDM is always looking for ways to live up to its mission statement, Doing Good, Doing More.
About DGDM
Through its subsidiary Black Bird Potentials, DGDM manufactures and sells CBD products, including CBD Oils, gummies and pet treats, and CBD-infused personal care products, as well as hand sanitizer gel and spray products. In addition, Black Bird is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. Black Bird is the exclusive distributor in the U. S. and Canada for MiteXstream, a plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee and house plants, as well as molds and mildew. EPA approval of MiteXstream is expected in late 2020.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information including statements that include the words "believes," "expects," "anticipate," or similar expressions. Such forward looking-statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof. Information concerning these and other factors can be found in the company's filings with the SEC, including its Forms 10-K, 10-Q, and 8-K, which can be obtained on the SEC's website at http://www.sec.gov.
Contact:
Eric Newlan
Vice President
enewlan@digitaldevelopmentpartners.com
$DGDM NEWS OUT!!!
Election Results Expand the Legal Cannabis Footprint by Four States, Boosting Prospective Sales for DGDM's Proven Disruptive Pesticide Product Targeted to MJ Growers
Newsfile Corp.
Newsfile Corp
Flower Mound, Texas--(Newsfile Corp. - November 12, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today addressed the expanding prospects, post-election, for its disruptive pesticide product, MiteXstream, following favorable legal cannabis votes in Arizona, New Jersey, Montana and South Dakota.
2020-2025 Growth. US recreational and medical cannabis industry sales are expected to be $19 billion for 2020, $24 billion for 2021 and, by 2025, with the four additions this month and expected newcomers, including New York, sales are industry sales are expected to reach $45 billion (Source: Brightfield Group).
Big Indoor Grows Need Protection. "Indoor grows are quite susceptible to troublesome infestations of spider mites and other pests and outbreaks of mold and mildew - the pests can kill the plants, while mold and mildew can spoil the harvest. Plant-based MiteXstream treats these problems the grow through the day of harvest without state testing failures - that is our disruptive competitive advantage," said Fabian Deneault, President of DGDM. "We continue to anticipate a December 2020 EPA approval of MiteXstream."
East Coast Density. "As legal cannabis continues to penetrate the densely populated Northeast Corridor - D.C. to Boston - the demand on grows to produce cannabis products will require efficient production techniques, and we believe MiteXstream will be a significant player in that effort," Mr. Deneault added.
DGDM: Doing Good, Doing More. DGDM is always looking for ways to live up to its mission statement, Doing Good, Doing More.
About DGDM
Through its subsidiary Black Bird Potentials, DGDM manufactures and sells CBD products, including CBD Oils, gummies and pet treats, and CBD-infused personal care products, as well as hand sanitizer gel and spray products. In addition, Black Bird is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. Black Bird is the exclusive distributor in the U. S. and Canada for MiteXstream, a plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee and house plants, as well as molds and mildew. EPA approval of MiteXstream is expected in late 2020.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information including statements that include the words "believes," "expects," "anticipate," or similar expressions. Such forward looking-statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof. Information concerning these and other factors can be found in the company's filings with the SEC, including its Forms 10-K, 10-Q, and 8-K, which can be obtained on the SEC's website at http://www.sec.gov.
Contact:
Eric Newlan
Vice President
enewlan@digitaldevelopmentpartners.com
$DGDM News out!!
Election Results Expand the Legal Cannabis Footprint by Four States, Boosting Prospective Sales for DGDM's Proven Disruptive Pesticide Product Targeted to MJ Growers
Newsfile Corp.
Newsfile Corp
Flower Mound, Texas--(Newsfile Corp. - November 12, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today addressed the expanding prospects, post-election, for its disruptive pesticide product, MiteXstream, following favorable legal cannabis votes in Arizona, New Jersey, Montana and South Dakota.
2020-2025 Growth. US recreational and medical cannabis industry sales are expected to be $19 billion for 2020, $24 billion for 2021 and, by 2025, with the four additions this month and expected newcomers, including New York, sales are industry sales are expected to reach $45 billion (Source: Brightfield Group).
Big Indoor Grows Need Protection. "Indoor grows are quite susceptible to troublesome infestations of spider mites and other pests and outbreaks of mold and mildew - the pests can kill the plants, while mold and mildew can spoil the harvest. Plant-based MiteXstream treats these problems the grow through the day of harvest without state testing failures - that is our disruptive competitive advantage," said Fabian Deneault, President of DGDM. "We continue to anticipate a December 2020 EPA approval of MiteXstream."
East Coast Density. "As legal cannabis continues to penetrate the densely populated Northeast Corridor - D.C. to Boston - the demand on grows to produce cannabis products will require efficient production techniques, and we believe MiteXstream will be a significant player in that effort," Mr. Deneault added.
DGDM: Doing Good, Doing More. DGDM is always looking for ways to live up to its mission statement, Doing Good, Doing More.
About DGDM
Through its subsidiary Black Bird Potentials, DGDM manufactures and sells CBD products, including CBD Oils, gummies and pet treats, and CBD-infused personal care products, as well as hand sanitizer gel and spray products. In addition, Black Bird is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. Black Bird is the exclusive distributor in the U. S. and Canada for MiteXstream, a plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee and house plants, as well as molds and mildew. EPA approval of MiteXstream is expected in late 2020.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information including statements that include the words "believes," "expects," "anticipate," or similar expressions. Such forward looking-statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof. Information concerning these and other factors can be found in the company's filings with the SEC, including its Forms 10-K, 10-Q, and 8-K, which can be obtained on the SEC's website at http://www.sec.gov.
Contact:
Eric Newlan
Vice President
enewlan@digitaldevelopmentpartners.com
Volume picking up. Something brewing??
Good call BB $AAWC
Jev i agree. I believe there is a huge short position here. End of the month will be telling. Hang in there till then. GLTY
$HYLN highlighted on Kramer's Mad Money last night, could explain the pre-market buying. JMHO
Thanks a lot Goldman. Can't believe they downgraded
News: $DGDM Provides Business Results Update Ahead of 3Q Report in Light of 2Q Results
Flower Mound, Texas--(Newsfile Corp. - October 15, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today provided an update with respect to its ongoing business operations in light of recent announcements and its 2Q results.
Product Sales and Distribution. "Year over year, our unaudited sales from the six months ended June 30, 2019, compared to the same period of 2020 grew by about 700%, from $4,840 to $35,874; but the really encouraging news is that customers continue to tell us that our CBD products, whether they be oils or topicals, are superior to other brands," said Fabian Deneault, President of DGDM. "Our results for the nine months ended September 30, 2020, are expected to show similar improvement over 2019, and we have only just this month begun to roll-out of our products across our Montana distributor's 1,000-store network," added Mr. Deneault.
Expanding Sales in All Facets. The Company has begun to market its disruptive MiteXstream biopesticide product ahead of its expected December 2020 EPA approval. Recently, Mr. Deneault expanded on earlier comments regarding the Company's expectations for MiteXstream, "we continue to believe that MiteXstream will prove to be the game changer, both in a business sense and in a sales sense for us, we thought it would be from the moment we developed it. We cannot wait to begin to get this into the hands of growers and farmers as soon as EPA certification is secured." Mr. Deneault also advised that the Company expected to be begin deriving revenues from a planned small hemp processing effort separate and apart from its previously announced plans for a full-scall Montana hemp processing facility.
DGDM: Doing Good, Doing More. DGDM is always looking for ways to live up to its mission statement, Doing Good, Doing More.
About DGDM
Through its subsidiary Black Bird Potentials, DGDM manufactures and sells CBD products, including CBD Oils, gummies and pet treats, and CBD-infused personal care products, as well as hand sanitizer gel and spray products. In addition, Black Bird is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. Black Bird is the exclusive distributor in the U. S. and Canada for MiteXstream, a plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee and house plants, as well as molds and mildew. EPA approval of MiteXstream is expected in late 2020.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information including statements that include the words "believes," "expects," "anticipate," or similar expressions. Such forward looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof. Information concerning these and other factors can be found in the company's filings with the SEC, including its Forms 10-K, 10-Q, and 8-K, which can be obtained on the SEC's website at http://www.sec.gov.
Contact:
Eric Newlan
Vice President
enewlan@digitaldevelopmentpartners.com
News: DGDM Provides Business Results Update Ahead of 3Q Report in Light of 2Q Results
Flower Mound, Texas--(Newsfile Corp. - October 15, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today provided an update with respect to its ongoing business operations in light of recent announcements and its 2Q results.
Product Sales and Distribution. "Year over year, our unaudited sales from the six months ended June 30, 2019, compared to the same period of 2020 grew by about 700%, from $4,840 to $35,874; but the really encouraging news is that customers continue to tell us that our CBD products, whether they be oils or topicals, are superior to other brands," said Fabian Deneault, President of DGDM. "Our results for the nine months ended September 30, 2020, are expected to show similar improvement over 2019, and we have only just this month begun to roll-out of our products across our Montana distributor's 1,000-store network," added Mr. Deneault.
Expanding Sales in All Facets. The Company has begun to market its disruptive MiteXstream biopesticide product ahead of its expected December 2020 EPA approval. Recently, Mr. Deneault expanded on earlier comments regarding the Company's expectations for MiteXstream, "we continue to believe that MiteXstream will prove to be the game changer, both in a business sense and in a sales sense for us, we thought it would be from the moment we developed it. We cannot wait to begin to get this into the hands of growers and farmers as soon as EPA certification is secured." Mr. Deneault also advised that the Company expected to be begin deriving revenues from a planned small hemp processing effort separate and apart from its previously announced plans for a full-scall Montana hemp processing facility.
DGDM: Doing Good, Doing More. DGDM is always looking for ways to live up to its mission statement, Doing Good, Doing More.
About DGDM
Through its subsidiary Black Bird Potentials, DGDM manufactures and sells CBD products, including CBD Oils, gummies and pet treats, and CBD-infused personal care products, as well as hand sanitizer gel and spray products. In addition, Black Bird is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. Black Bird is the exclusive distributor in the U. S. and Canada for MiteXstream, a plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee and house plants, as well as molds and mildew. EPA approval of MiteXstream is expected in late 2020.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information including statements that include the words "believes," "expects," "anticipate," or similar expressions. Such forward looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof. Information concerning these and other factors can be found in the company's filings with the SEC, including its Forms 10-K, 10-Q, and 8-K, which can be obtained on the SEC's website at http://www.sec.gov.
Contact:
Eric Newlan
Vice President
enewlan@digitaldevelopmentpartners.com
$PIXY green today. Hopefully it continues!!!
Stocks for the Meatless Future (NASDAQ: BYND) (OTC: DGDM) (NYSE: HRL) Very interesting story by Market Watch
$GTEH Bids stacking up!!
$DGDM NEWS OUT!!!
DGDM's Hemp Processing Plant For Hemp-Based Alternative Meat Opportunity Set to Capitalize on Investor-Friendly "Opportunity Zone"
Newsfile Corp.
Newsfile Corp
Flower Mound, Texas and Ronan, Montana--(Newsfile Corp. - October 12, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today announced that the first Black Bird American Hemp™ processing plant will be located in an investor-friendly "Opportunity Zone" in Montana. The Company is evaluating competing Montana properties within Opportunity Zones on which to locate its hemp processing facility that will focus on producing high-quality hemp protein products for sale into the rapidly expanding alternative meat, or meatless food, industry. A final determination is expected by the end of October 2020.
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7327/65713_b1c80934b4f6e928_001full.jpg
Opportunity Zones: An Economic Engine. "By building our plant within an Opportunity Zone, we are confident that we will be able to fund plant construction through direct investments of private equity, due to the extremely beneficial tax benefits that would be available to certain investors, or by other available means, including through the use of industrial bonds or traditional financing sources," said Fabian Deneault, President of DGDM. "This strategy will permit us to minimize dilution to our current shareholders," Mr. Deneault added.
According to the Council of Economic Advisors report on the impact of tax incentives on Opportunity Zone investment entitled The Impact of Opportunity Zones: An Initial Assessment, through 2019, the tax incentives had brought $52 billion in new investment in Opportunity Zones. Information regarding Opportunity Zones is available from the Company via e-mail request to: enewlan@digitaldevelopmentpartners.com.
Minimizing Shareholder Dilution. To avoid significant and unnecessary shareholder dilution, DGDM's management has determined that the first hemp processing facility of Black Bird American Hemp will be financed through private sources, which are expected to include one or more of the following: private equity, bank loans and industrial revenue bonds.
DGDM: Doing Good, Doing More. DGDM is always looking for ways to live up to its mission statement, Doing Good, Doing More.
About DGDM
Through its subsidiary Black Bird Potentials, DGDM manufactures and sells CBD products, including CBD Oils, gummies and pet treats, and CBD-infused personal care products, as well as hand sanitizer gel and spray products. In addition, Black Bird is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. Black Bird is the exclusive distributor in the U. S. and Canada for MiteXstream, a plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee and house plants, as well as molds and mildew. EPA approval of MiteXstream is expected in late 2020.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information including statements that include the words "believes," "expects," "anticipate," or similar expressions. Such forward looking-statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof. Information concerning these and other factors can be found in the company's filings with the SEC, including its Forms 10-K, 10-Q, and 8-K, which can be obtained on the SEC's website at http://www.sec.gov.
Contact:
Eric Newlan
Vice President
enewlan@digitaldevelopmentpartners.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/65713
https://www.newsfilecorp.com/newsinfo/65713/130
$DGDM NEWS OUT!!!!
DGDM's Hemp Processing Plant For Hemp-Based Alternative Meat Opportunity Set to Capitalize on Investor-Friendly "Opportunity Zone"
Newsfile Corp.
Newsfile Corp
Flower Mound, Texas and Ronan, Montana--(Newsfile Corp. - October 12, 2020) - Digital Development Partners, Inc. (OTC PINK: DGDM) ("DGDM" or the "Company"), doing business as Black Bird Potentials Inc., the exclusive distributor of MiteXstream biopesticide and manufacturer of Grizzly Creek Naturals CBD products (GrizzlyCreekNaturals.com), today announced that the first Black Bird American Hemp™ processing plant will be located in an investor-friendly "Opportunity Zone" in Montana. The Company is evaluating competing Montana properties within Opportunity Zones on which to locate its hemp processing facility that will focus on producing high-quality hemp protein products for sale into the rapidly expanding alternative meat, or meatless food, industry. A final determination is expected by the end of October 2020.
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7327/65713_b1c80934b4f6e928_001full.jpg
Opportunity Zones: An Economic Engine. "By building our plant within an Opportunity Zone, we are confident that we will be able to fund plant construction through direct investments of private equity, due to the extremely beneficial tax benefits that would be available to certain investors, or by other available means, including through the use of industrial bonds or traditional financing sources," said Fabian Deneault, President of DGDM. "This strategy will permit us to minimize dilution to our current shareholders," Mr. Deneault added.
According to the Council of Economic Advisors report on the impact of tax incentives on Opportunity Zone investment entitled The Impact of Opportunity Zones: An Initial Assessment, through 2019, the tax incentives had brought $52 billion in new investment in Opportunity Zones. Information regarding Opportunity Zones is available from the Company via e-mail request to: enewlan@digitaldevelopmentpartners.com.
Minimizing Shareholder Dilution. To avoid significant and unnecessary shareholder dilution, DGDM's management has determined that the first hemp processing facility of Black Bird American Hemp will be financed through private sources, which are expected to include one or more of the following: private equity, bank loans and industrial revenue bonds.
DGDM: Doing Good, Doing More. DGDM is always looking for ways to live up to its mission statement, Doing Good, Doing More.
About DGDM
Through its subsidiary Black Bird Potentials, DGDM manufactures and sells CBD products, including CBD Oils, gummies and pet treats, and CBD-infused personal care products, as well as hand sanitizer gel and spray products. In addition, Black Bird is a licensed grower of industrial hemp under the Montana Hemp Pilot Program. Black Bird is the exclusive distributor in the U. S. and Canada for MiteXstream, a plant-based biopesticide effective in the eradication of spider mites, a pest that destroys crops, especially cannabis, hops, coffee and house plants, as well as molds and mildew. EPA approval of MiteXstream is expected in late 2020.
Notice Regarding Forward-Looking Statements
This news release contains forward-looking information including statements that include the words "believes," "expects," "anticipate," or similar expressions. Such forward looking-statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof. Information concerning these and other factors can be found in the company's filings with the SEC, including its Forms 10-K, 10-Q, and 8-K, which can be obtained on the SEC's website at http://www.sec.gov.
Contact:
Eric Newlan
Vice President
enewlan@digitaldevelopmentpartners.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/65713
https://www.newsfilecorp.com/newsinfo/65713/130